1. Inicio
  2. Publicaciones
  3. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Gallego-Durán R
  • Ampuero J
  • Maya-Miles D
  • Pastor-Ramírez H
  • Montero-Vallejo R
  • Rivera-Esteban J
  • Álvarez-Amor L
  • Pareja MJ
  • Rico MC
  • Millán R
  • Robles-Frías MJ
  • Aller R
  • Rojas Á
  • Muñoz-Hernández R
  • Gil-Gómez A
  • Gato S
  • García-Lozano M
  • Abad J
  • Calleja JL
  • Andrade RJ
  • González-Rodríguez Á
  • García-Monzón C
  • Andreola F
  • Pericás JM
  • Jalan R
  • Martín-Bermudo F
  • Romero-Gómez M

Unidades

Abstract

AIM: We aimed to assess the role of FGF21 in metabolic dysfunction-associated steatotic liver disease (MASLD) at a multi-scale level. METHODS: We used human MASLD pathology samples for FGF21 gene expression analyses (qPCR and RNAseq), serum to measure circulating FGF21 levels and DNA for genotyping the FGF21 rs838133 variant in both estimation and validation cohorts. A hepatocyte-derived cell line was exposed to free fatty acids at different timepoints. Finally, C57BL/6J mice were fed a high-fat and choline-deficient diet (CDA-HFD) for 16 weeks to assess hepatic FGF21 protein expression and FGF21 levels by ELISA. RESULTS: A significant upregulation in FGF21 mRNA expression was observed in the liver analysed by both qPCR (fold change 5.32 ± 5.25 vs. 0.59 ± 0.66; p = 0.017) and RNA-Seq (3.5 fold; FDR: 0.006; p < 0.0001) in MASLD patients vs. controls. Circulating levels of FGF21 were increased in patients with steatohepatitis vs. bland steatosis (386.6 ± 328.9 vs. 297.9 ± 231.5 pg/mL; p = 0.009). Besides, sex, age, A-allele from FGF21, GG genotype from PNPLA3, ALT, type 2 diabetes mellitus and BMI were independently associated with MASH and significant fibrosis in both estimation and validation cohorts. In vitro exposure of Huh7.5 cells to high concentrations of free fatty acids (FFAs) resulted in overexpression of FGF21 (p < 0.001). Finally, Circulating FGF21 levels and hepatic FGF21 expression were found to be significantly increased (p < 0.001) in animals under CDA-HFD. CONCLUSIONS: Hepatic and circulating FGF21 expression was increased in MASH patients, in Huh7.5 cells under FFAs and in CDA-HFD animals. The A-allele from the rs838133 variant was also associated with an increased risk of steatohepatitis and significant and advanced fibrosis in MASLD patients.

© 2024 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.

Datos de la publicación

ISSN/ISSNe:
2050-6406, 2050-6414

United European Gastroenterology Journal  SAGE PUBLICATIONS INC

Tipo:
Article
Páginas:
1056-1068
PubMed:
38894596

Citas Recibidas en Web of Science: 6

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • FGF21; MASH; MASLD; NAFLD; NASH; fibroblast growth factor 21; gene expression; hepatokine; metabolic syndrome; steatohepatitis

Compartir